Cold Plasma Technology Receives FDA Clearance for Precision Cancer Surgery

Can Cold Plasma Transform Cancer Surgery?

Jerome Canady Research Institute's cold plasma system has received FDA clearance for a novel cancer treatment approach that could transform surgical oncology. The Canady Helios Cold Plasma (CHCP) system, now FDA-cleared for intraoperative use, demonstrates non-thermal, non-contact irreversible electroporation capabilities that selectively target and kill cancer cells while preserving surrounding healthy tissue. This breakthrough technology addresses a critical need for precise tumor ablation at surgical margins, potentially reducing local recurrence rates in cancer patients.

The CHCP system represents a significant advancement over conventional irreversible electroporation (IRE) platforms like NanoKnife and Galvanize Knife, which rely on direct electrode insertion and can produce thermal effects with associated procedural risks including venous thrombosis, biliary complications, and gastrointestinal injuries. The CHCP technology operates at room temperature (22-24°C) and utilizes a unique combination of high-frequency electric fields with plasma-generated reactive oxygen and nitrogen species to create what researchers term a "Plasma Treated Electromagnetic Field" (PTEF). This field induces nanoscale pores in cancer cell membranes, disrupting cellular homeostasis and triggering cell death through non-thermal mechanisms. The system delivers controlled voltage (15-30V) that translates to field strengths of approximately 1005-2010 V/cm, enabling precise titration of the electroporation effect based on tumor characteristics and location. Researchers have systematically demonstrated the system's ability to induce voltage-dependent and time-dependent membrane permeabilization across multiple breast cancer subtypes, including triple-negative, hormone receptor-positive, and HER2-positive cell lines, suggesting broad applicability across different cancer types.

How Was CHCP's Safety and Efficacy Established?

The development of CHCP builds upon nearly a decade of research into cold atmospheric plasma (CAP) for cancer therapy. The Jerome Canady Research Institute has progressively advanced this technology from preclinical studies demonstrating selective cancer cell targeting to a completed Phase I clinical trial (NCT04267575) that established safety and feasibility in patients with advanced solid tumors. Histopathological analyses from this trial revealed selective tumor cell death characterized by membrane disruption and cytoplasmic leakage at treated margins, while adjacent non-malignant tissues remained structurally preserved. These findings align with in vitro studies showing that CHCP enables functional delivery of therapeutic macromolecules like siRNA across compromised cell membranes, opening possibilities for enhanced drug delivery. The technology's ability to induce selective cancer cell death without thermal damage represents a significant advantage over conventional ablation methods that often cause collateral tissue injury and delayed healing. The non-contact nature of the system also permits treatment of irregular or otherwise inaccessible post-resection margins, addressing a major challenge in surgical oncology where residual microscopic disease can persist despite clear gross margins.

Dr. Jerome Canady, principal investigator and developer of the technology, has emphasized the precision and reproducibility of CHCP-induced electroporation. "What distinguishes our approach is the ability to achieve controlled, non-thermal electroporation without direct tissue contact, potentially revolutionizing how we address microscopic residual disease at surgical margins," he stated following FDA clearance. The research team has further highlighted that unlike conventional IRE systems, CHCP operates through a dual-action mechanism: rapid electric-field-mediated poration followed by slower oxidative injury from plasma-generated reactive species. This mechanism appears particularly effective against tumor cells, which typically exhibit disordered lipid organization, depolarized resting potentials, elevated oxidative stress, and impaired membrane repair capabilities compared to normal cells. The selective nature of this effect may explain the promising outcomes observed in early clinical applications, where patients with microscopic residual disease who received CHCP application exhibited improved post-operative outcomes compared to standard approaches. Researchers have also noted potential immunomodulatory benefits, as irreversible membrane damage can promote the release of damage-associated molecular patterns that activate antigen-presenting cells and prime adaptive immune responses against tumor antigens.

Will CHCP Change the Oncological Landscape?

The market for non-thermal ablation technologies has expanded significantly in recent years, with conventional IRE systems like NanoKnife generating substantial revenue despite their limitations. The global market for tumor ablation technologies is projected to reach $2.4 billion by 2026, with non-thermal approaches gaining increasing market share due to their precision and reduced complication rates. CHCP's non-contact approach potentially addresses several limitations of needle-based IRE systems, including the risk of bleeding, infection, and tumor seeding along needle tracks. Additionally, while conventional IRE requires general anesthesia with complete neuromuscular blockade to prevent muscle contractions during high-voltage pulse delivery, CHCP's non-contact nature may eliminate this requirement, simplifying clinical protocols and potentially reducing procedure costs. The technology also avoids the "heat sink" effect that limits thermal ablation near major blood vessels, potentially expanding the range of treatable lesions. These advantages position CHCP as a disruptive technology in the surgical oncology market, with potential applications extending beyond intraoperative use to minimally invasive interventional procedures.

Looking forward, Jerome Canady Research Institute is planning larger clinical trials to establish efficacy across multiple cancer types and treatment scenarios. The company is exploring expanded indications beyond the current intraoperative application, including potential use in minimally invasive laparoscopic and robotic surgical platforms. Research is also underway to optimize treatment parameters for different tumor types and to investigate combination approaches with immunotherapy, as the immunogenic cell death pathway triggered by CHCP may enhance response to checkpoint inhibitors. The technology's non-thermal, non-contact nature makes it particularly promising for sensitive anatomical locations where conventional ablation carries high risk, such as central nervous system tumors, pancreatic cancer, and lesions adjacent to major vascular or biliary structures. If larger trials confirm the promising results seen in Phase I, CHCP could establish a new paradigm in surgical oncology, where complete tumor resection is complemented by selective ablation of microscopic residual disease at margins, potentially improving long-term survival rates across multiple cancer types.

Industry Context: The development and FDA clearance of CHCP comes at a pivotal time in cancer therapy, as the field increasingly shifts toward precision-based, tissue-sparing approaches that minimize collateral damage while maximizing tumor control. This technology addresses the persistent challenge of local recurrence following apparently complete tumor resection, a problem that affects 20-40% of patients across various solid tumor types. The non-thermal, selective nature of CHCP aligns with the broader trend toward personalized cancer treatments that target specific tumor vulnerabilities while preserving patient quality of life. For investors and pharmaceutical companies, CHCP represents an opportunity in the rapidly growing field of physical oncology, where device-based approaches complement traditional drug therapies to improve overall treatment outcomes.

Summary

The Jerome Canady Research Institute has received FDA clearance for its Canady Helios Cold Plasma (CHCP) system, a breakthrough technology that uses non-thermal, non-contact irreversible electroporation to selectively destroy cancer cells during surgery while preserving healthy tissue. Operating at room temperature, the system combines high-frequency electric fields with plasma-generated reactive species to create nanoscale pores in cancer cell membranes, triggering cell death without thermal damage. This approach addresses critical limitations of conventional irreversible electroporation systems, which require direct electrode insertion and can cause complications including thrombosis and tissue injury. The technology builds on nearly a decade of research and a completed Phase I clinical trial that demonstrated safety and feasibility in patients with advanced solid tumors, showing selective tumor cell death while preserving adjacent healthy tissue. Unlike needle-based systems, CHCP's non-contact nature eliminates risks of bleeding, infection, and tumor seeding, while potentially simplifying clinical protocols by avoiding the need for neuromuscular blockade. The system has shown effectiveness across multiple breast cancer subtypes and may offer immunomodulatory benefits by triggering immune responses against tumor antigens. With the global tumor ablation market projected to reach $2.4 billion by 2026, CHCP is positioned as a disruptive technology with applications extending beyond current intraoperative use to minimally invasive procedures. The Jerome Canady Research Institute is planning larger clinical trials across multiple cancer types and exploring combination approaches with immunotherapy, particularly for sensitive anatomical locations where conventional ablation carries high risk. If confirmed in larger trials, this technology could establish a new paradigm in surgical oncology by complementing complete tumor resection with selective ablation of microscopic residual disease, potentially improving survival rates across various cancer types.